tbuckley/cabot-search huggingface dataset:
2016 Consensus statement on return to sport from the First World Congress in Sports Physical Therapy, Bern
Authors: Clare L Ardern, Philip Glasgow, Anthony Schneiders, Erik Witvrouw, Benjamin Clarsen, Ann Cools, Boris Gojanovic, Steffan Griffin, Karim M Khan, Håvard Moksnes, Stephen A Mutch, Nicola Phillips, Gustaaf Reurink, Robin Sadler, Karin Grävare Silbernagel, Kristian Thorborg, Arnlaug Wangensteen, Kevin E Wilk, Mario Bizzini
Journal: British Journal of Sports Medicine (2016)

Deciding when to return to sport after injury is complex and multifactorial-an exercise in risk management. Return to sport decisions are made every day by clinicians, athletes and coaches, ideally in a collaborative way. The purpose of this consensus statement was to present and synthesise current evidence to make recommendations for return to sport decision-making, clinical practice and future research directions related to returning athletes to sport. A half day meeting was held in Bern, Switzerland, after the First World Congress in Sports Physical Therapy. 17 expert clinicians participated. 4 main sections were initially agreed upon, then participants elected to join 1 of the 4 groups-each group focused on 1 section of the consensus statement. Participants in each group discussed and summarised the key issues for their section before the 17-member group met again for discussion to reach consensus on the content of the 4 sections. Return to sport is not a decision taken in isolation at the end of the recovery and rehabilitation process. Instead, return to sport should be viewed as a continuum, paralleled with recovery and rehabilitation. Biopsychosocial models may help the clinician make sense of individual factors that may influence the athlete's return to sport, and the Strategic Assessment of Risk and Risk Tolerance framework may help decision-makers synthesise information to make an optimal return to sport decision. Research evidence to support return to sport decisions in clinical practice is scarce. Future research should focus on a standardised approach to defining, measuring and reporting return to sport outcomes, and identifying valuable prognostic factors for returning to sport.
Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression
Authors: Peter A. Campochiaro, Arshad Khanani, Michael Singer, Sunil Patel, David Boyer, Pravin Dugel, Saleema Kherani, Barbara Withers, Laura Gambino, Kevin Peters, Mitchell Brigell
Journal: Ophthalmology (2016)
Common and rare<i>CARD14</i>gene variants affect the antitumour necrosis factor response among patients with psoriasis
Authors: P. Coto‐Segura, D. González‐Fernández, A. Batalla, J. Gómez, L. González‐Lara, R. Queiro, B. Alonso, S. Iglesias, E. Coto
Journal: British Journal of Dermatology (2016)

The CARD14 gene encodes a protein that enhances nuclear factor (NF)-κB activation and the upregulation of proinflammatory pathway genes. CARD14 is upregulated in psoriatic vs. normal skin, and rare and common CARD14 variants have been associated with the risk of developing psoriasis. Our hypothesis was that CARD14 variants could also influence the response to antitumour necrosis factor (anti-TNF) therapies among patients with psoriasis.To determine whether CARD14 gene variants were linked to a significant positive anti-TNF response in patients with psoriasis.DNA from 116 patients with psoriasis was subjected to next-generation sequencing of the CARD14 gene. All of the patients were nonresponders or had contraindications to conventional systemic treatments.A reduction of at least 75% in Psoriasis Area and Severity Index (PASI 75) at week 24 was considered a positive response to treatment. In total 116 patients (79 responders and 37 nonresponders) were next-generation sequenced, and we identified five nucleotide variants that would result in missense amino acid changes. These variants were determined in all of the patients, and allele and genotype frequencies were compared between the two groups. We found a significantly higher frequency of rs11652075 CC (p.Arg820Trp) among the group with a positive response (P = 0.01, odds ratio 3.71, 95% confidence interval 1.30-10.51). Furthermore, among responders, six patients were heterozygous carriers of the rare p.Glu422Lys variant, and two patients were heterozygous for p.Arg682Trp (P = 0.04).The common CARD14 p.Arg820Trp variant might have a significant effect on the response to anti-TNF therapies among patients with psoriasis. In addition, rare CARD14 missense variants could also predispose to a better response.
Insanity defenses: contested or conceded?
Authors: J L Rogers, J D Bloom, S M Manson
Journal: American Journal of Psychiatry (1984)

The authors examined 316 Oregon criminal cases in which the accused successfully pleaded the insanity defense. Prosecutors agreed to the insanity verdict in more than four out of five cases. In most cases all examining experts diagnosed the defendant as psychotic. The smaller number of defendants who were diagnosed by the state hospital staff as displaying only personality disorders accounted for a disproportionately large percentage of the contested trials. Observing that Oregon's insanity defense system is run by consensus, the authors suggest a reorientation of the insanity defense debate.
Seasonal influenza and 2009 H1N1 influenza vaccination coverage among pregnant women - 10 states, 2009-10 influenza season.
Authors: I. B. Ahluwalia, D. J. Jamieson, D. V. D'Angelo, J. A. Singleton, T. Santibanez, G. Euler, C. Weinbaum
Journal: MMWR Morbidity and Mortality Weekly Report (2010)
Abstract P5-12-11: Duration of ovarian function suppression for premenopausal women with hormone receptor-positive breast cancer: Retrospective study
Authors: Y Ozaki, N Tamura, M Utiyama, J Masuda, S Koganemaru, Y Miura, Y Tanabe, T Ogura, M Kadowaki, D Miura, H Kawabata, T Takano
Journal: Cancer Research (2016)

Abstract Background: Although tamoxifen (TAM) plus ovarian function suppression (OFS) is one of standard adjuvant treatments in premenopausal women with hormone receptor-positive breast cancer, the optimal duration of OFS has not been clearly established. Patients and Methods: We retrospectively reviewed data of premenopausal patients with breast cancer, who received TAM and OFS (goserelin or leuprorelin) as adjuvant therapy between February 2004 and April 2015. The primary analysis was to compare disease-free survival (DFS) between patients who received OFS shorter than 3 years and those who received OFS longer than 3 years. The analyses were performed with Cox proportional hazards models and propensity score matching models. Results: We analyzed 206 premenopausal patients with hormone receptor-positive breast cancer. Median follow-up time was 56 months. Median age was 42 years (range, 24-52 years). Twenty six per cent of the patients had positive axillary nodes and 30% had received neo-adjuvant or adjuvant chemotherapy. Median duration of OFS was 26 months. Duration of OFS was shorter than three years (OFS &amp;lt; 3y) in 74% patients, and longer than three years (OFS &amp;gt; 3y) in 26% patients. Patients with node-positive disease were more in OFS &amp;gt; 3y group than in OFS &amp;lt; 3y group, and more patients received chemotherapy in OFS &amp;gt; 3y group than in OFS &amp;lt; 3y group. 5-year disease-free survival (DFS) was 96.1%. DFS in patients aged ≤ 40 years and aged &amp;gt; 40 years were 91.8% and 99.0%, respectively (p=0.0223). Propensity score matching model showed that DFS was not significantly different between patients in OFS &amp;lt; 3y group and those in OFS &amp;gt; 3y group (97.4%, 91.6%; p=0.2406). In patients aged ≤ 40 years and/or those who received chemotherapy, 5-year DFS was 96.7% in OFS &amp;lt; 3y group, 90.1% in OFS &amp;gt; 3y group (p=0.3011). Conclusions: Our data suggest that OFS &amp;lt; 3y is not inferior to OFS &amp;gt; 3y for premenopausal women with hormone receptor-positive breast cancer as adjuvant endocrine therapy. A randomized trial is needed to establish the optimal OFS duration for these patients. Citation Format: Ozaki Y, Tamura N, Utiyama M, Masuda J, Koganemaru S, Miura Y, Tanabe Y, Ogura T, Kadowaki M, Miura D, Kawabata H, Takano T. Duration of ovarian function suppression for premenopausal women with hormone receptor-positive breast cancer: Retrospective study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-12-11.
Abstract B52: PTK6 inhibition as a novel strategy to reverse EMT and suppress metastasis of triple negative breast cancer
Authors: Koichi Ito, Sun Hee Park, Hanna Y. Irie
Journal: Cancer Research (2016)

Abstract Triple negative breast cancer (TNBC) poses clinical challenges due to intrinsic biological aggressiveness and lack of targeted therapies. Hypothesis: Protein tyrosine kinase 6 (PTK6) regulates epithelial-mesenchymal transition (EMT) of TNBC, as well as their growth and metastatic potential. We evaluated PTK6 as a promising therapeutic target to prevent metastases of TNBC. Experimental Procedures: Levels of PTK6 have prognostic significance; higher transcript levels are associated with poor outcomes for patients. We modulated the level of PTK6 in breast epithelial and TNBC cell lines, and determined effects on growth, migration, epithelial-mesenchymal transition and metastasis formation in vivo. Results: PTK6 promotes EMT; overexpression of kinase active PTK6 (Y447F) in non-transformed MCF10A cells promotes migration, suppresses expression of epithelial markers (E-cadherin, claudin-1), and increases expression of N-cadherin and fibronectin, markers of mesenchymal cells. Promotion of EMT is dependent on PTK6 kinase activity as overexpression of catalytically inactive PTK6 (K219M) failed to induce EMT. Downregulation of PTK6 in mesenchymal TNBC cells (human MDA-MB231 or murine MMTV-myc) restores epithelial properties and suppresses migration and growth in 3-D MatrigelTM cultures. PTK6 inhibition-induced E-cadherin expression is due to decreased expression of Snail, a transcriptional repressor of E-cadherin. PTK6 downregulation promotes the proteasome-dependent degradation of Snail protein, via a mechanism that is independent of GSK3β activity. PTK6 inhibition promotes anoikis of TNBC cells in vitro and prevents metastases in vivo; decreased metastasis formation is directly linked to PTK6-dependent regulation of EMT and E-cadherin levels. Conclusions: Our studies support PTK6 inhibition as a novel strategy to impair metastasis of TNBC cells via reversal of mesenchymal properties. The kinase dependency of EMT regulation by PTK6 highlight the potential for clinical translation of recently developed PTK6 kinase inhibitors as a therapeutic strategy for patients with triple negative breast cancers. Citation Format: Koichi Ito, Sun Hee Park, Hanna Y. Irie. PTK6 inhibition as a novel strategy to reverse EMT and suppress metastasis of triple negative breast cancer. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr B52.
The Association of Prenatal Exposure to Perfluorinated Chemicals with Glucocorticoid and Androgenic Hormones in Cord Blood Samples: The Hokkaido Study
Authors: Houman Goudarzi, Atsuko Araki, Sachiko Itoh, Seiko Sasaki, Chihiro Miyashita, Takahiko Mitsui, Hiroyuki Nakazawa, Katsuya Nonomura, Reiko Kishi
Journal: Environmental Health Perspectives (2016)

Background:Perfluorinated chemicals (PFCs) disrupt cholesterol homeostasis. All steroid hormones are derived from cholesterol, and steroid hormones such as glucocorticoids and androgenic hormones mediate several vital physiologic functions. However, the in utero effects of PFCs exposure on the homeostasis of these steroid hormones are not well understood in humans.Objectives:We examined the relationship between prenatal exposure to perfluorooctane sulfonate (PFOS)/perfluorooctanoate (PFOA) and cord blood levels of glucocorticoid and androgenic hormones.Methods:We conducted a hospital-based birth cohort study between July 2002 and October 2005 in Sapporo, Japan (n = 514). In total, 185 mother–infant pairs were included in the present study. Prenatal PFOS and PFOA levels in maternal serum samples were measured using liquid chromatography–tandem mass spectrometry (LC-MS-MS). Cord blood levels of glucocorticoid (cortisol and cortisone) and androgenic hormones [dehydroepiandrosterone (DHEA) and androstenedione] were also measured in the same way.Results:We found a dose–response relationship of prenatal PFOS, but not PFOA, exposure with glucocorticoid levels after adjusting for potential confounders. Cortisol and cortisone concentrations were –23.98-ng/mL (95% CI: –0.47.12, –11.99; p for trend = 0.006) and –63.21-ng/mL (95% CI: –132.56, –26.72; p for trend < 0.001) lower, respectively, in infants with prenatal PFOS exposure in the fourth quartile compared with those in the first quartile. The highest quartile of prenatal PFOS exposure was positively associated with a 1.33-ng/mL higher DHEA level compared with the lowest quartile (95% CI: 0.17, 1.82; p for trend = 0.017), whereas PFOA showed a negative association with DHEA levels (quartile 4 vs. quartile 1: –1.23 ng/mL, 95% CI: –1.72, –0.25; p for trend = 0.004). We observed no significant association between PFCs and androstenedione levels.Conclusions:Our results indicate that prenatal exposure to PFCs is significantly associated with glucocorticoid and DHEA levels in cord blood.Citation:Goudarzi H, Araki A, Itoh S, Sasaki S, Miyashita C, Mitsui T, Nakazawa H, Nonomura K, Kishi R. 2017. The association of prenatal exposure to perfluorinated chemicals with glucocorticoid and androgenic hormones in cord blood samples: the Hokkaido Study. Environ Health Perspect 125:111–118; http://dx.doi.org/10.1289/EHP142
Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone
Authors: Trevor T. Price, Monika L. Burness, Ayelet Sivan, Matthew J. Warner, Renee Cheng, Clara H. Lee, Lindsey Olivere, Karrie Comatas, John Magnani, H. Kim Lyerly, Qing Cheng, Chad M. McCall, Dorothy A. Sipkins
Journal: Science Translational Medicine (2016)

Breast cancer cells traffic to and from the peripheral blood within specific vascular niches, and this migration can be therapeutically targeted.
Recovery from schizophrenic psychosis
Authors: H V Szymanski, J C Simon, N Gutterman
Journal: American Journal of Psychiatry (1983)

Knowledge of changes in patients' symptoms during hospitalization is crucial in planning treatment for acute psychotic exacerbation of chronic schizophrenia. Biweekly assessment of symptoms in 44 schizophrenic patients during the first 4 weeks of hospitalization showed that rapid recovery from psychotic symptoms occurred early in hospitalization; recovery from depression and anxiety was less complete. The rapid recovery in the first few weeks of hospital treatment supports the use of brief hospitalization for psychotic relapse. It is important to focus follow-up treatment on patients' relative lack of recovery in the hospital from depression and anxiety.
Uniform criteria for childhood acute lymphoblastic leukemia risk classification.
Authors: M Smith, A Bleyer, W Crist, S Murphy, S E Sallan
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.2.680 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8636788 Uniform criteria for childhood acute lymphoblastic leukemia risk classification. M SmithxM SmithSearch for articles by this author , A BleyerxA BleyerSearch for articles by this author , W CristxW CristSearch for articles by this author , S MurphyxS MurphySearch for articles by this author , S E SallanxS E SallanSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.2.680 PDF "Uniform criteria for childhood acute lymphoblastic leukemia risk classification.." Journal of Clinical Oncology, 14(2), pp. 680–681© 1996 by American Society of Clinical Oncology
Brain and Mind or the Nervous System of Man.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Is treatment for alcoholism effective in persons on methadone maintenance?
Authors: B Stimmel, M Cohen, V Sturiano, R Hanbury, D Korts, G Jackson
Journal: American Journal of Psychiatry (1983)

A randomized prospective study of 625 drug addicts on methadone maintenance revealed that 105 (17%) were active alcoholics, 47 (8%) were inactive alcoholics, and 473 (76%) were not alcoholics. The active alcoholics were randomly assigned to abstinence therapy, controlled drinking with behavior modification, or a control group receiving the usual clinic services. There were no differences between treatment and control groups at baseline and during follow-up of up to 2 1/2 years, and there was no relation between remission and treatment, suggesting that the effectiveness of currently employed specific interventions for alcoholism in active alcoholic addicts maintained on methadone cannot be demonstrated.
Analysis For Loss Of 13q Heterozygosity Using STR Or SNP Analysis Can Replace Analysis Of FLT3-ITD To Detect Prognostically Adverse AML
Authors: Susanne Schnittger, Simone Weber, Sonja Schindela, Andreas Roller, Tamara Alpermann, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach
Journal: Blood (2013)
Phase I study of concurrent therapy using TS1 and docetaxel for gastric cancer
Authors: Y. Rino, T. Imada, Y. Takanashi
Journal: Journal of Clinical Oncology (2004)

4152 Background: Gastric cancer is commonly treated with TS1-based chemotherapy, but a subsequent treatment method is necessary for patients disease relapse×recurrence. In this study we investigated the safety of combination of docetaxel [Taxotere (T)] with TS1 in such patients. Methods: Nine patients with unresectable or relapsed gastric cancer came to the hospital every 2 weeks. They were allocated to 3 treatment groups. TS1 was administered according to the usual schedule, while T was administered in a dosage of 25, 30 or 35 mg/m2 every two weeks. The patients were monitored for adverse reactions. Results: No adverse reactions of grade 3 or greater severity occurred in the patient groups administered T at 25 or 30 mg/m2, but they did manifest in 2 of the 3 patients administered T at 35 mg/m2. In some patients with adverse reactions, the reactions were strong even after the dosage of T was reduced, but reduction of the dosage of TS1 was effective in alleviating the symptoms. Conclusions: The recommended dosage of T when administered concurrently with the usual TS1 dosage is 30 mg/m2. In addition, reduction of the TS1 dosage is effective for alleviating intolerable adverse reactions to the concurrent chemotherapy. No significant financial relationships to disclose.
MTR-04DOWN-REGULATION OF MDR1 BY DKK3 ATTENUATES CHEMORESISTANCE TO TEMOZOLOMIDE, AND POTENTIATES ITS ANTI-TUMOR EFFECTS
Authors: Toshitaka Fujihara, Teruyoshi Kageji, Yoshihumi Mizobuchi, Ryotaro Otsuka, Keiko Kitazato, Keijiro Hara, Keniji Shono, Kohei Nakajima, Hideo Mure, Kazuyuki Kuwayama, Shinji Nagahiro
Journal: Neuro-Oncology (2015)

BACKGROUND AND PURPOSE: Some patients with glioblastoma multiforme (GBM) do not respond to temozolomide (TMZ), a target for the multidrug resistance transporter MDR1/ABCB1. The genotype of the MDR1 exon12 C1236T single nucleotide polymorphism is reported as a predictive factor of the efficacy of TMZ in GBM. The expression of MDR1 is inhibited via JNK activation. Elsewhere we reported that the overexpression of DKK3 exerted anti-tumor effects in association with JNK activation. However, the regulation of MDR1 by DKK3 remains to be elucidated. We tested our hypothesis that the DKK3-induced activation of JNK down-regulates MDR1, thereby attenuating the chemoresistance of GBM to TMZ. METHODS: We compared the results of treating GBM cells, i.e. U87MG- and primary TGB105 cells with TMZ alone and with TMZ plus Ad-DKK3. RESULTS: The viability of U87MG- and TGB105 cells was not significantly affected by TMZ or Ad-DKK3 alone. However, in combination, they augmented cell death. In a GBM xenograft mice model, treatment with TMZ or Ad-DKK3 exerted anti-tumor effects that were enhanced by their combined administration without affecting the animals' body weight. The increased expression of MDR1 in GBM cells was reduced by Ad-DKK3. The decrease in MDR1 expression elicited by Ad-DKK3 was inversely correlated with the expression of p-JNK, c-JUN, and p-c-JUN but not of JNK, which was eliminated by the JNK inhibitor SP600125. Our findings suggest that the Ad-DKK3-induced activation of JNK downregulates MDR1, thereby attenuating the chemoresistance of GBM cells to TMZ and enhancing its anti-tumor effects. CONCLUSION: Ad-DKK3 may not only exert anti-tumor effects but also serve as an adjuvant therapy for GBM. Chemotherapy targeting JNK may be a promising treatment option.